SG11201802830QA - Combination therapy with glutaminase inhibitors and immuno-oncology agents - Google Patents

Combination therapy with glutaminase inhibitors and immuno-oncology agents

Info

Publication number
SG11201802830QA
SG11201802830QA SG11201802830QA SG11201802830QA SG11201802830QA SG 11201802830Q A SG11201802830Q A SG 11201802830QA SG 11201802830Q A SG11201802830Q A SG 11201802830QA SG 11201802830Q A SG11201802830Q A SG 11201802830QA SG 11201802830Q A SG11201802830Q A SG 11201802830QA
Authority
SG
Singapore
Prior art keywords
immuno
combination therapy
oncology agents
glutaminase inhibitors
glutaminase
Prior art date
Application number
SG11201802830QA
Inventor
Susan Molineaux
Matthew Gross
Susan Bromley
Francesco Parlati
Mark Bennett
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of SG11201802830QA publication Critical patent/SG11201802830QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11201802830QA 2015-10-05 2016-10-04 Combination therapy with glutaminase inhibitors and immuno-oncology agents SG11201802830QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237287P 2015-10-05 2015-10-05
US201662323179P 2016-04-15 2016-04-15
PCT/US2016/055316 WO2017062354A1 (en) 2015-10-05 2016-10-04 Combination therapy with glutaminase inhibitors and immuno-oncology agents

Publications (1)

Publication Number Publication Date
SG11201802830QA true SG11201802830QA (en) 2018-05-30

Family

ID=58447081

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201802830QA SG11201802830QA (en) 2015-10-05 2016-10-04 Combination therapy with glutaminase inhibitors and immuno-oncology agents

Country Status (10)

Country Link
US (3) US10258619B2 (en)
EP (1) EP3359150A4 (en)
JP (1) JP6971239B2 (en)
KR (1) KR20180059544A (en)
CN (1) CN108601767A (en)
AU (1) AU2016335991A1 (en)
CA (1) CA3000996A1 (en)
IL (1) IL258500A (en)
SG (1) SG11201802830QA (en)
WO (1) WO2017062354A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2920168T (en) 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
AU2016335991A1 (en) 2015-10-05 2018-05-10 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
EP3681498B1 (en) * 2017-09-14 2022-10-05 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
WO2019089952A1 (en) * 2017-11-03 2019-05-09 Calithera Biosciences, Inc. Conjoint therapy with glutaminase inhibitors
AU2020339737A1 (en) * 2019-08-30 2022-03-17 Vestlandets Innovasjonsselskap As Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
CN111643669A (en) * 2020-06-30 2020-09-11 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Application of glutaminase inhibitor in preparation of medicine for treating psoriasis
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
WO2023068820A1 (en) * 2021-10-19 2023-04-27 오가노이드사이언스 주식회사 Composition for treating or preventing cancer
WO2023202652A1 (en) * 2022-04-21 2023-10-26 Jacobio Pharmaceuticals Co., Ltd. Pharmaceutical combination and use thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
JP3979783B2 (en) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド Ophthalmic composition comprising galactomannan polymer and borate
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
WO2002076939A2 (en) 2001-02-05 2002-10-03 Exegenics Inc. Cysteine protease inhibitors
EP1613308A4 (en) * 2003-03-27 2008-02-20 Lankenau Inst Medical Res Novel methods for the treatment of cancer
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2578680C (en) 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
WO2009017822A2 (en) 2007-08-02 2009-02-05 Amgen Inc. Pi3 kinase modulators and methods of use
JP5583592B2 (en) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
CN101951930A (en) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 To useful oral of the recovery of body function or through the intestinal compositions
DK2389352T3 (en) * 2009-01-26 2019-07-29 Univ Pennsylvania Arginase inhibitors and methods of use
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
MX2013005434A (en) 2010-11-18 2013-09-26 Deuteria Pharmaceuticals Inc 3-deutero-pomalidomide.
CA2824599C (en) * 2010-12-31 2020-03-10 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (en) 2011-09-06 2011-09-06 Turun Yliopisto Combination therapy
CN103030597B (en) 2011-09-30 2014-10-01 南昌滨西科技有限公司 Kidney type glutaminase inhibitor as well as preparation method and application kidney type glutaminase inhibitor
WO2013059437A1 (en) * 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EA201692166A1 (en) * 2011-11-21 2017-07-31 Калитера Байосайенсиз Инк. GLETAMINASE HETEROCYCLIC INHIBITORS
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
AU2013266243A1 (en) 2012-05-24 2014-12-18 Beth Israel Deaconess Medical Center, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
BR112015005243A2 (en) 2012-09-10 2017-07-04 Celgene Corp Methods For Treating Locally Advanced Breast Cancer
ES2690829T3 (en) 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for the selection of patients who respond to treatment
LT2920168T (en) 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
KR20150085078A (en) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. Glutamase inhibitors and method of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
AU2013356241A1 (en) * 2012-12-03 2015-07-09 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
ES2733546T3 (en) * 2013-03-15 2019-11-29 Bristol Myers Squibb Co IDO inhibitors
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
MX2016005283A (en) 2013-10-25 2017-02-20 Pharmacyclics Llc Treatment using bruton's tyrosine kinase inhibitors and immunotherapy.
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US20170165364A1 (en) * 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
MX2016016364A (en) 2014-06-13 2017-04-06 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors.
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016004413A2 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
US10517844B2 (en) 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
BR112017020780A2 (en) 2015-03-30 2018-06-26 Calithera Biosciences Inc Glutaminase inhibitor administration methods
KR20170132333A (en) 2015-04-06 2017-12-01 칼리테라 바이오사이언시즈, 인코포레이티드 Treatment of lung cancer with glutaminase inhibitor
CA2994256A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
TW201725044A (en) 2015-10-01 2017-07-16 基利科學股份有限公司 Combination of a BTK inhibitor and a checkpoint inhibitor for treating cancers
AU2016335991A1 (en) 2015-10-05 2018-05-10 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
ES2905823T3 (en) 2016-05-20 2022-04-12 Biohaven Therapeutics Ltd Use of riluzole, riluzole prodrugs, or riluzole analogs with immunotherapies to treat cancers
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
US20180055825A1 (en) 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
CN109982703A (en) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 With the combination treatment of glutamine enzyme inhibitor
WO2018165516A1 (en) 2017-03-10 2018-09-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2019089952A1 (en) * 2017-11-03 2019-05-09 Calithera Biosciences, Inc. Conjoint therapy with glutaminase inhibitors

Also Published As

Publication number Publication date
CA3000996A1 (en) 2017-04-13
JP6971239B2 (en) 2021-11-24
US20210361649A1 (en) 2021-11-25
AU2016335991A1 (en) 2018-05-10
EP3359150A4 (en) 2019-11-06
KR20180059544A (en) 2018-06-04
CN108601767A (en) 2018-09-28
US10258619B2 (en) 2019-04-16
US20190231776A1 (en) 2019-08-01
IL258500A (en) 2018-05-31
US20170095473A1 (en) 2017-04-06
US10940148B2 (en) 2021-03-09
WO2017062354A1 (en) 2017-04-13
EP3359150A1 (en) 2018-08-15
JP2018529780A (en) 2018-10-11

Similar Documents

Publication Publication Date Title
IL249476A0 (en) Combination therapy with glutaminase inhibitors
IL269462A (en) Mdm2 inhibitors and therapeutic methods using the same
IL265922A (en) Tyk2 inhibitors and uses thereof
IL258500A (en) Combination therapy with glutaminase inhibitors and immuno-oncology agents
IL266109A (en) Tyk2 inhibitors and uses thereof
HK1256997A1 (en) Tyk2 inhibitors and uses thereof
HK1248690A1 (en) Tyk2 inhibitors and uses thereof
IL251618A0 (en) Combination therapy comprising ox40 binding agonists and tigit inhibitors
EP3116872A4 (en) Combination therapy with glutaminase inhibitors
EP3592354A4 (en) Combination therapy with glutaminase inhibitors
HK1254129A1 (en) Methods of administering glutaminase inhibitors
IL259570A (en) Combination treatments and uses and methods thereof
IL260222A (en) Bromodomain and extra-terminal protein inhibitor combination therapy
EP3503886A4 (en) Combination therapy with glutaminase inhibitors
PT3532459T (en) Lsd1 inhibitors and medical uses thereof
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
EP3503893A4 (en) Combination therapy with glutaminase inhibitors
IL267238A (en) Heparanase inhibitors and use thereof
GB201702160D0 (en) Inhibitors for use in therapy
HK1250926A1 (en) Inhibitors and their uses
GB201418809D0 (en) Therapeutic agents and uses thereof
HUE045185T2 (en) New therapeutic compound and use in therapy
IL267243A (en) Heparanase inhibitors and use thereof
GB201512216D0 (en) Agents uses and methods
GB201505975D0 (en) Inhibitors and their uses